Edition:
United States

Molecular Templates Inc (MTEM.OQ)

MTEM.OQ on NASDAQ Stock Exchange Capital Market

7.03USD
25 May 2018
Change (% chg)

$0.27 (+3.99%)
Prev Close
$6.76
Open
$6.76
Day's High
$7.03
Day's Low
$6.73
Volume
9,427
Avg. Vol
18,713
52-wk High
$13.25
52-wk Low
$3.90

Latest Key Developments (Source: Significant Developments)

Molecular Templates Reports Qtrly Loss Per Share ‍$0.26​
Wednesday, 28 Mar 2018 04:30pm EDT 

March 28 (Reuters) - Molecular Templates Inc ::MOLECULAR TEMPLATES, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS.Q4 REVENUE $800,000 VERSUS $400,000.‍AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS TOTALED $58.9 MILLION​.CO'S CURRENT CASH BALANCE IS EXPECTED TO FUND OPERATIONS INTO LATE 2019​.QTRLY LOSS PER SHARE ‍$0.26​.  Full Article

Molecular Templates Provides Corporate Update And Outlines 2018 Milestones
Friday, 5 Jan 2018 08:00am EST 

Jan 5 (Reuters) - Molecular Templates Inc ::MOLECULAR TEMPLATES PROVIDES CORPORATE UPDATE AND OUTLINES 2018 MILESTONES.MOLECULAR TEMPLATES INC - ‍ EXPECTED TO FILE IND FOR HER2 AND/OR PD-L1 PROGRAMS BUSINESS DEVELOPMENT IN Q4 2018​.MOLECULAR TEMPLATES INC - EXPECTS TO FILE IND FOR HER2 AND/OR PD-L1 PROGRAMS IN Q4 2018.  Full Article

Molecular Templates appoints Adam Cutler as CFO
Tuesday, 14 Nov 2017 04:15pm EST 

Nov 14 (Reuters) - Molecular Templates Inc :Molecular Templates strengthens management team with appointment of Adam Cutler as Chief Financial Officer.Molecular Templates Inc - ‍announced appointment of Adam Cutler as Chief Financial Officer, effective Monday, November 13, 2017​.  Full Article

Molecular Templates Q3 loss per share $0.62
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Molecular Templates Inc ::Molecular Templates, Inc. Reports third quarter 2017 financial results.Q3 revenue $600,000.Q3 loss per share $0.62.Molecular Templates Inc - ‍MT-3724 advancing in clinical trials with new data expected in 1H18​.  Full Article

AbCheck and Molecular Templates collaborate to discover therapeutic oncology leads
Wednesday, 25 Oct 2017 10:12am EDT 

Oct 25 (Reuters) - Molecular Templates Inc ::Says Abcheck will use Absieve discovery platform to deliver antibodies against biological targets selected by Molecular Templates​.Says ‍further details were not disclosed​.  Full Article

Takeda Pharmaceutical Co reports 10.9 pct stake in Molecular Templates - SEC Filing‍​
Thursday, 10 Aug 2017 04:26pm EDT 

Aug 10 (Reuters) - Molecular Templates Inc :Takeda Pharmaceutical Company reports 10.9 percent stake in Molecular Templates Inc as of August 1, 2017 - SEC Filing‍​.  Full Article

Takeda Pharmaceutical and Molecular Templates announce research and licensing collaboration
Thursday, 3 Aug 2017 09:00am EDT 

Aug 3 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda Pharmaceutical and molecular templates announce multi-target research and licensing collaboration to develop next-generation oncology therapies​.Takeda Pharmaceutical - ‍collaboration will apply molecular templates' engineered toxin bodies technology platform to potential therapeutic targets provided by takeda​.Takeda Pharmaceutical Co - Takeda will have right to exercise exclusive options to obtain license rights to products resulting from collaboration.Takeda Pharmaceutical Co Ltd says additional terms of agreement are not being disclosed.Takeda Pharmaceutical says it will make an equity investment and molecular templates is eligible to receive upfront payments, milestone payments​.Says ‍signed the agreement through its wholly owned subsidiary, millennium pharmaceuticals​.  Full Article

Threshold Pharmaceuticals qtrly earnings per share $0.02
Monday, 31 Jul 2017 05:45pm EDT 

July 31 (Reuters) - Threshold Pharmaceuticals Inc :Threshold pharmaceuticals reports second quarter financial results.Q2 revenue $3.0 million.Threshold Pharmaceuticals Inc qtrly earnings per share $0.02.  Full Article

Threshold Pharma says first patient dosed in clinical trial of evofosfamide, ipilimumab
Tuesday, 13 Jun 2017 08:01am EDT 

June 13 (Reuters) - Threshold Pharmaceuticals Inc ::Threshold Pharmaceuticals announces first patient dosed in immunotherapy clinical trial of evofosfamide and ipilimumab.Threshold Pharmaceuticals Inc - ‍phase 1 clinical trial will evaluate effect of ipilimumab and evofosfamide (TH-302) in advanced solid tumors​.Threshold Pharmaceuticals Inc - ‍immune-related response evaluation criteria in solid tumors (irrecist) response rate is primary endpoint​.  Full Article

OBI Pharma buys TH-3424 from Threshold Pharmaceuticals
Thursday, 1 Jun 2017 05:00am EDT 

June 1 (Reuters) - OBI Pharma Inc <4174.TWO>:OBI Pharma announces acquisition of TH-3424 from Threshold Pharmaceuticals.OBI Pharma says product will be renamed OBI-3424 effective immediately.OBI Pharma - Threshold to transfer to co its ownership rights as well as preclinical,manufacturing data for OBI-3424 for undisclosed, upfront one-time payment.OBI Pharma - plans to accelerate development of OBI-3424, with IND application filing with U.S. FDA planned for early 2018.  Full Article

BRIEF-Molecular Templates Q1 Loss Per Share $0.32

* MOLECULAR TEMPLATES, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS